UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington D. C. 20549

                                    FORM 8-K

              CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                      SECURITIES AND EXCHANGE ACT OF 1934.

                                 August 4, 2005
                Date of Report (Date of Earliest Event Reported)

                             DNAPrint genomics, Inc.
               (Exact name of Registrant as specified in charter)

                         Commission File Number: 0-31905

                Utah                                      59-2780520
        (State of Incorporation)                   (I.R.S. Employer I.D. No)

                     900 Cocoanut Avenue, Sarasota, FL 34236
                    (Address of Principal Executive Offices)

                                 (941) 366-3400
              (Registrant's Telephone Number, Including Area Code)

         Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

Item 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS.

      As previously  reported on July 8, 2005,  the  Registrant  entered into an
agreement  to  purchase,   and  simultaneously  closed  upon  the  purchase  of,
securities  comprising or convertible into an 18% equity interest in Biofrontera
AG  ("Biofrontera"),  a  German  company  in the  pharmaceutical  business.  The
Registrant      purchased     the     interest     in      Biofrontera      from
Technologie-Beteiligungs-Gesellschaft  mbH ("tbg"),  an  instrumentality  of the
German government.  The securities purchased were shares of Biofrontera's series
A Preferred Stock, as well as certain convertible debt instruments.

      On  August  4,  2005  the  Registrant  converted  two  of the  three  debt
instruments  purchased from tbg into 267,299 total shares of Biofrontera  common
stock.  The Registrant  paid  Biofrontera a subscription  price of 1.00 Euro per
share in exchange for the issuance of the Biofrontera  stock.  The Registrant is
still waiting to convert the remaining debt  instrument  into 98,145 shares upon
receipt of German government approval.  At that time, the Registrant will pay an
additional subscription price of 98,145 Euros. Upon conversion of this remaining
debt  instrument,  the  Registrant's  acquisition  of an 18% equity  interest in
Biofrontera will be complete.

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.

                                       DNAPrint genomics, Inc.

                                       By: /s/ Richard Gabriel
                                           -------------------------------------
                                           Richard Gabriel, President
{"company-data": {"conformed-name": "DNAPRINT GENOMICS INC", "cik": "0001127354", "assigned-sic": "8731", "irs-number": "592780520", "state-of-incorporation": "UT", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-31905", "film-number": "051013718"}, "business-address": {"street1": "900 COCONUT AVE.", "city": "SARASOTA", "state": "FL", "zip": "34231", "phone": "9413663400"}, "mail-address": {"street1": "900 COCOANUT AVENUE", "street2": "NO SUITE", "city": "SARASOTA", "state": "FL", "zip": "34231"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington D. C. 20549

                                    FORM 8-K

              CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                      SECURITIES AND EXCHANGE ACT OF 1934.

                                 August 4, 2005
                Date of Report (Date of Earliest Event Reported)

                             DNAPrint genomics, Inc.
               (Exact name of Registrant as specified in charter)

                         Commission File Number: 0-31905

                Utah                                      59-2780520
        (State of Incorporation)                   (I.R.S. Employer I.D. No)

                     900 Cocoanut Avenue, Sarasota, FL 34236
                    (Address of Principal Executive Offices)

                                 (941) 366-3400
              (Registrant's Telephone Number, Including Area Code)

         Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))
Item 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS.

      As previously  reported on July 8, 2005,  the  Registrant  entered into an
agreement  to  purchase,   and  simultaneously  closed  upon  the  purchase  of,
securities  comprising or convertible into an 18% equity interest in Biofrontera
AG  ("Biofrontera"),  a  German  company  in the  pharmaceutical  business.  The
Registrant      purchased     the     interest     in      Biofrontera      from
Technologie-Beteiligungs-Gesellschaft  mbH ("tbg"),  an  instrumentality  of the
German government.  The securities purchased were shares of Biofrontera's series
A Preferred Stock, as well as certain convertible debt instruments.

      On  August  4,  2005  the  Registrant  converted  two  of the  three  debt
instruments  purchased from tbg into 267,299 total shares of Biofrontera  common
stock.  The Registrant  paid  Biofrontera a subscription  price of 1.00 Euro per
share in exchange for the issuance of the Biofrontera  stock.  The Registrant is
still waiting to convert the remaining debt  instrument  into 98,145 shares upon
receipt of German government approval.  At that time, the Registrant will pay an
additional subscription price of 98,145 Euros. Upon conversion of this remaining
debt  instrument,  the  Registrant's  acquisition  of an 18% equity  interest in
Biofrontera will be complete.

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.

                                       DNAPrint genomics, Inc.

                                       By: /s/ Richard Gabriel
                                           -------------------------------------
                                           Richard Gabriel, President